| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma (NCT07700979) | Akeso | 2026-08-20 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps (NCT07755371) | Akeso | 2026-08-10 |
| A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer (NCT07591090) | Akeso | 2026-07-17 |
| A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer (NCT07669779) | Akeso | 2026-07-10 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer (NCT07623356) | Akeso | 2026-07-07 |
| A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma (NCT07636772) | Akeso | 2026-06-22 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer (NCT07560124) | Akeso | 2026-06-06 |
| A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations (NCT07619001) | Akeso | 2026-06-01 |
| Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer (NCT07412613) | Akeso | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis (NCT07502222) | Akeso | 2026-04-07 |
| A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (NCT07449780) | Akeso | 2026-03-31 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis (NCT07436234) | Akeso | 2026-03-02 |
| A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases (NCT07357220) | Akeso | 2026-03-02 |
| Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) (NCT07263919) | Akeso | 2025-12-19 |
| A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects (NCT07340476) | Akeso | 2025-12-11 |
| A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease (NCT07301502) | Akeso | 2025-12-01 |
| A Study of AK138D1 in Advanced Malignant Tumors (NCT07281326) | Akeso | 2025-10-22 |
| A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects (NCT07043283) | Akeso | 2025-10-20 |
| AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment (NCT07158840) | Akeso | 2025-09-05 |
| A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma (NCT07023315) | Akeso | 2025-08-14 |
| A Study of AK146D1 for Injection in Advanced Solid Tumors (NCT07067567) | Akeso | 2025-08-07 |
| A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. (NCT07052253) | Akeso | 2025-07-18 |
| Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer (NCT06928389) | Akeso | 2025-07-08 |
| A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors (NCT06929663) | Akeso | 2025-07-02 |
| A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC (NCT06984718) | Akeso | 2025-06-25 |
| A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (NCT07010263) | Akeso | 2025-06-13 |
| AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer (NCT06951503) | Akeso | 2025-05-27 |
| AK129 Combination Therapy for Advanced Solid Tumors (NCT06943820) | Akeso | 2025-05-21 |
| A Clinical Study of AK139 in Healthy Subjects (NCT06947109) | Akeso | 2025-05-06 |
| A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer (NCT06938321) | Akeso | 2025-04-30 |
| AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) (NCT06860789) | Akeso | 2025-02-28 |
| A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors (NCT06730386) | Akeso | 2025-02-24 |
| AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer (NCT06767527) | Akeso | 2025-02-07 |
| A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (NCT06767540) | Akeso | 2025-01-23 |
| AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer (NCT06646055) | Akeso | 2025-01-21 |
| A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma (NCT06642792) | Akeso | 2025-01-17 |
| A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) (NCT06756126) | Akeso | 2024-12-30 |
| A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104) (NCT07547787) | Akeso | 2024-12-26 |
| AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors (NCT06691360) | Akeso | 2024-12-01 |
| A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC (NCT06617416) | Akeso | 2024-11-12 |
| An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer (NCT06560112) | Akeso | 2024-11-12 |
| A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects (NCT06641388) | Akeso | 2024-11-04 |
| A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (NCT06601335) | Akeso | 2024-10-30 |
| AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer (NCT06591520) | Akeso | 2024-10-20 |
| A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (NCT06530251) | Akeso | 2024-09-24 |
| A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma (NCT06586294) | Akeso | 2024-09-10 |
| A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (NCT06371157) | Akeso | 2024-08-02 |
| A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis (NCT06700499) | Akeso | 2024-07-08 |
| A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06341335) | Akeso | 2024-06-19 |
| A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis (NCT06383468) | Akeso | 2024-04-30 |
| A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia (NCT06387420) | Akeso | 2024-04-29 |
| A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes (NCT06196203) | Akeso | 2024-02-07 |
| A Study of AK131 in Patients With Advanced Solid Tumors (NCT06166888) | Akeso | 2024-01-10 |
| A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis (NCT06378697) | Akeso | 2023-11-22 |
| A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NCT05990127) | Akeso | 2023-11-14 |
| Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (NCT05960955) | Akeso | 2023-11-13 |
| A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis (NCT06092762) | Akeso | 2023-11-06 |
| A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (NCT05951608) | Akeso | 2023-10-16 |
| To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis (NCT06061471) | Akeso | 2023-09-22 |
| AK104 for Recurrent or Metastatic Vulvar Cancer (NCT05932212) | Akeso | 2023-08-25 |
| AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (NCT05840016) | Akeso | 2023-08-17 |
| AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer (NCT05904379) | Akeso | 2023-07-13 |
| A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma (NCT05256472) | Akeso | 2023-07-06 |
| A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (NCT05868876) | Akeso | 2023-06-29 |
| A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer (NCT05859750) | Akeso | 2023-05-25 |
| A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (NCT05846867) | Akeso | 2023-05-08 |
| Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors (NCT05689853) | Akeso | 2023-04-14 |
| A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis (NCT06066125) | Akeso | 2023-03-31 |
| A Study of AK129 in Patients With Advanced Malignant Tumors (NCT05645276) | Akeso | 2023-03-02 |
| AK104 in Neoadjuvant Treatment of Cervical Cancer (NCT05227651) | Akeso | 2023-02-10 |
| Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients (NCT05636267) | Akeso | 2023-02-10 |
| A Study of AK130 in Patients With Advanced Malignant Tumors (NCT05653284) | Akeso | 2023-02-09 |
| A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection (NCT05489289) | Akeso | 2023-01-05 |
| Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors (NCT05559541) | Akeso | 2022-12-15 |
| AK112 in Advanced Non-Small Cell Lung Cancer (NCT05499390) | Akeso | 2022-11-09 |
| A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects (NCT05559554) | Akeso | 2022-10-25 |
| A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer (NCT05505825) | Akeso | 2022-08-26 |
| A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) (NCT05432492) | Akeso | 2022-08-03 |
| A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC (NCT05319431) | Akeso | 2022-06-28 |
| A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (NCT05382442) | Akeso | 2022-06-27 |
| A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer (NCT05235516) | Akeso | 2022-06-21 |
| A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors (NCT05393063) | Akeso | 2022-06-01 |
| A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer (NCT05215067) | Akeso | 2022-05-13 |
| A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (NCT05229497) | Akeso | 2022-05-04 |
| Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis (NCT05509361) | Akeso | 2022-04-08 |
| A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (NCT05227664) | Akeso | 2022-03-23 |
| A Clinical Study of AK115 in Healthy Subjects (NCT05286970) | Akeso | 2022-03-18 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 (NCT05200273) | Akeso | 2022-03-15 |
| A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors (NCT05235542) | Akeso | 2022-03-12 |
| AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC (NCT05247684) | Akeso | 2022-02-20 |
| A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma (NCT05244642) | Akeso | 2022-02-15 |
| A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia (NCT05260411) | Akeso | 2022-01-26 |
| Phase 3 Clinical Study of AK112 for NSCLC Patients (NCT05184712) | Akeso | 2022-01-25 |
| A Study of AK112 in Advanced Malignant Tumors (NCT05214482) | Akeso | 2022-01-22 |
| Study of AK119 in Subjects With Advanced Solid Tumors (NCT05173792) | Akeso | 2021-12-22 |
| A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis (NCT05120297) | Akeso | 2021-11-29 |
| A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia (NCT05255458) | Akeso | 2021-11-04 |
| A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia (NCT05255094) | Akeso | 2021-11-03 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis (NCT06035354) | Akeso | 2021-11-03 |
| A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (NCT05142423) | Akeso | 2021-11-03 |